These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 26049755)

  • 21. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.
    Woods DM; Sodré AL; Villagra A; Sarnaik A; Sotomayor EM; Weber J
    Cancer Immunol Res; 2015 Dec; 3(12):1375-85. PubMed ID: 26297712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
    Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
    Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
    Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
    Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
    Hamid O; Carvajal RD
    Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Immune System Alterations in Hodgkin Lymphoma.
    Grover NS; Savoldo B
    Curr Hematol Malig Rep; 2017 Aug; 12(4):358-369. PubMed ID: 28780614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
    Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
    Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
    Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
    Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
    Shin DS; Ribas A
    Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the programmed death-1 pathway in lymphoid neoplasms.
    Ok CY; Young KH
    Cancer Treat Rev; 2017 Mar; 54():99-109. PubMed ID: 28242522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-1 and PD-L1 blockade in gastrointestinal malignancies.
    Lote H; Cafferkey C; Chau I
    Cancer Treat Rev; 2015 Dec; 41(10):893-903. PubMed ID: 26412280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune Checkpoint Therapy in Renal Cell Carcinoma.
    Lee CH; Motzer RJ
    Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
    Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Festino L; Botti G; Lorigan P; Masucci GV; Hipp JD; Horak CE; Melero I; Ascierto PA
    Drugs; 2016 Jun; 76(9):925-45. PubMed ID: 27229745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospects for targeting PD-1 and PD-L1 in various tumor types.
    Kim JW; Eder JP
    Oncology (Williston Park); 2014 Nov; 28 Suppl 3():15-28. PubMed ID: 25387682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune checkpoint blockade in lymphoid malignancies.
    Thanarajasingam G; Thanarajasingam U; Ansell SM
    FEBS J; 2016 Jun; 283(12):2233-44. PubMed ID: 26807978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
    Hirai M; Kitahara H; Kobayashi Y; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
    Int J Oncol; 2017 Jan; 50(1):41-48. PubMed ID: 27922697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed cell death-1 inhibition in lymphoma.
    Hawkes EA; Grigg A; Chong G
    Lancet Oncol; 2015 May; 16(5):e234-45. PubMed ID: 25943068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
    Gravelle P; Burroni B; Péricart S; Rossi C; Bezombes C; Tosolini M; Damotte D; Brousset P; Fournié JJ; Laurent C
    Oncotarget; 2017 Jul; 8(27):44960-44975. PubMed ID: 28402953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.
    Chen DS; Irving BA; Hodi FS
    Clin Cancer Res; 2012 Dec; 18(24):6580-7. PubMed ID: 23087408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.